Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome

Sammanfattning

Acute respiratory distress syndrome (ARDS) is associated with diffuse inflammation, alveolar epithelial damage, and leakage of plasma proteins into the alveolar space, which together contribute to inactivation of pulmonary surfactant and respiratory failure. Exogenous surfactant delivery is therefore considered to hold potential for ARDS treatment, but clinical trials with natural derived surfactant or synthetic surfactant containing a surfactant protein C (SP-C) analogue have been negative. Synthetic surfactant CHF5633, containing analogues of SP-B and SP-C, may be effective against ARDS. The aim here was to compare treatment effects of CHF5633 and animal-derived surfactant poractant alfa in animal model of ARDS. ARDS was induced in adult New Zealand rabbits by mild lung lavages followed by injurious ventilation until respiratory failure (P/F ratio

Nyckelord

ARDS model; CHF5633; inflammation; lung function; synthetic pulmonary surfactant

Publicerad i

Physiological Reports
2021, volym: 9, nummer: 1, artikelnummer: e14700
Utgivare: WILEY

SLU författare

• Rising, Anna

  • Institutionen för husdjurens biovetenskaper, Sveriges lantbruksuniversitet
    
  • Karolinska Institutet

Associerade SLU-program

Translationell och komparativ medicin

UKÄ forskningsämne

Fysiologi och anatomi

Publikationens identifierare

• DOI: https://doi.org/10.14814/phy2.14700

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/118681